Close Menu

NEW YORK (360Dx) – Six years after gaining the rights to a point-of-care diagnostic technology originally developed at Harvard University, Opko Health is readying a regulatory submission for an instrument and a prostate-specific antigen test based on the technology.

If successful, the platform, called Claros 1, could make quantitative immunodiagnostic testing readily accessible to physicians, simplifying testing procedures and increasing testing compliance among patients, a company executive said.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.